Efficacy of zinc administration in patients with hepatitis C virus-related chronic liver disease
| Autor: | Seiji Nakai, Takashi Himoto, Tsutomu Masaki, Shoichi Senda, Kazutaka Kurokochi, Michiko Matsuki, Naoki Hosomi, Seishiro Watanabe, M. Yachida, Shigeki Kuriyama, Akihiro Deguchi, Fumihiko Kinekawa |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Collagen Type IV Liver Cirrhosis Male medicine.medical_specialty Cirrhosis Time Factors Hepatitis C virus Iron Anti-Inflammatory Agents chemistry.chemical_element Administration Oral Zinc Hepacivirus Chronic liver disease medicine.disease_cause Gastroenterology Liver Function Tests Fibrosis Internal medicine medicine Organometallic Compounds Humans Hyaluronic Acid Hepatic encephalopathy Serum Albumin Aged Hepatitis business.industry Platelet Count Carnosine Hepatitis C Chronic Middle Aged medicine.disease chemistry Zinc Compounds Immunology Female Hepatic fibrosis business Biomarkers Copper |
| Zdroj: | Scandinavian journal of gastroenterology. 42(9) |
| ISSN: | 0036-5521 |
| Popis: | Zinc supplementation has been shown to contribute to inhibition of liver fibrosis and improvement in hepatic encephalopathy. However, little is known about the anti-inflammatory effect of zinc on hepatitis C virus (HCV)-related chronic liver disease (CLD). We therefore examined the effects of zinc administration on inflammatory activity and fibrosis in the liver of patients with HCV-related CLD.Polaprezinc, a complex of zinc and l-carnosine, was administrated at 225 mg/day for 6 months to 14 patients with HCV-related CLD, in addition to their ongoing prescriptions. Peripheral blood cell counts, liver-related biochemical parameters, serological markers for liver fibrosis, HCV-RNA loads, and serum levels of zinc and ferritin were evaluated before and after zinc administration.Serum zinc concentrations were positively correlated with hepatic reserve before zinc supplementation. A significant increase in serum zinc level was observed after zinc supplementation (64+/-15 versus 78+/-26 mg/dl, p=0.0156). Treatment with polaprezinc significantly decreased serum aminotransferase levels (aspartate aminotransferase (AST): 92+/-33 versus 63+/-23 IU/l, p=0.0004; alanine aminotransferase (ALT): 106+/-43 versus 65+/-32 IU/l, p=0.0002), whereas alkaline phosphatase levels were significantly increased (305+/-117 versus 337+/-118 U/l, p=0.0020). Serum ferritin levels were significantly decreased by treatment with polaprezinc (158+/-141 versus 101+/-80 ng/ml, p=0.0117). The reduction rate of ALT levels by polaprezinc was positively correlated with that of ferritin (r(2)=0.536, p=0.0389). There was a tendency toward a decrease in serum type IV collagen 7S levels after treatment with polaprezinc. However, administration of polaprezinc did not affect peripheral blood cell counts, other liver function tests, or HCV-RNA loads.These findings suggest that polaprezinc exerts an anti-inflammatory effect on the liver in patients with HCV-related CLD by reducing iron overload. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|